Drug profile · INN
aprepitant
APREPITANT APOTEX
aprepitant (APREPITANT APOTEX) is a neurokinin 1 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — aprepitant
- US status
- approved
- Class
- Alimentary tract and metabolism (A04)
- Route
- ORAL
- Patents
- 20
- Programs
- 13
- Data quality
- 0.89
Quick answer
aprepitant (APREPITANT APOTEX) is a neurokinin 1 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurokinin 1 receptor antagonist
Primary target: Substance-P receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12144815
Use of aprepitant for treating Alzheimer's disease
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11173118
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
granted -
US 11008309
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 10953018
Emulsion formulations of aprepitant
granted -
US 10858347
Multicyclic compounds and uses thereof
granted -
US 10624850
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
granted -
US 10500208
Emulsion formulations of aprepitant
granted -
US 10399963
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 9994558
Multicyclic compounds and methods of using same
granted -
US 9974793
Emulsion formulations of aprepitant
granted -
US 9974742
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
granted -
US 9974794
Emulsion formulations of aprepitant
granted -
US 9938258
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
granted -
US 9856241
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted
Frequently asked questions
What is aprepitant?
aprepitant (APREPITANT APOTEX) is a neurokinin 1 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for aprepitant?
APREPITANT APOTEX is a marketed brand name for aprepitant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aprepitant?
aprepitant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.